Umbralisib
A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths.
UNITY-NHL: response rates ~45-50% in relapsed MZL and FL (accelerated approval February 2021). UNITY-CLL (umbralisib-ublituximab) showed a possible overall-survival detriment; TG Therapeutics withdrew the drug in 2022 and the FDA revoked approval.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Relapsed marginal zone lymphoma and follicular lymphoma — Withdrawn 2022 |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Umbralisib" OR ABSTRACT:"Umbralisib" OR TITLE:"Ukoniq" OR ABSTRACT:"Ukoniq") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Umbralisib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductIdelalisib
Shares Indication withdrawal, PIK3CA / PI3K-alpha, Follicular lymphoma, PI3K / AKT / mTOR and the tag gap-fill.
- ProductCopanlisib
Shares Indication withdrawal, PIK3CA / PI3K-alpha, Follicular lymphoma, PI3K / AKT / mTOR and the tag gap-fill.
- ProductDuvelisib
Shares Indication withdrawal, PIK3CA / PI3K-alpha, PI3K / AKT / mTOR, Chronic lymphocytic leukaemia and the tag gap-fill.
- ProductTazemetostat
Shares Indication withdrawal, Follicular lymphoma and the tag gap-fill.
- ProductTemsirolimus
Shares PI3K / AKT / mTOR, Small-molecule kinase inhibitors and the tag gap-fill.
- ProductEnsartinib
Shares Small-molecule kinase inhibitors and the tag gap-fill.
- ProductDacomitinib
Shares Small-molecule kinase inhibitors and the tag gap-fill.
- ProductCeritinib
Shares Small-molecule kinase inhibitors and the tag gap-fill.